LANCE FOSTER: Open Payments
NPI 1891740502 · SPRINGDALE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$945 in 50 payments from 14 companies in 2025. Trend: 2023 $464 · 2024 $879 · 2025 $945
Food & beverage: $945
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 3 | $157 |
| Alkermes, Inc. | 5 | $106 |
| ABBVIE INC. | 6 | $104 |
| Otsuka America Pharmaceutical, Inc. | 5 | $92 |
| Corium, LLC | 11 | $86 |
| Neurocrine BioSciences, Inc. | 3 | $65 |
| E.R. Squibb & Sons, L.L.C. | 3 | $64 |
| Janssen Pharmaceuticals, Inc | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Collegium Pharmaceutical, Inc. | 3 | $47 |
Products named: Auvelity, ARISTADA, VRAYLAR, REXULTI, Azstarys, INGREZZA, COBENFY, INVEGA SUSTENNA.
Industry payments across AR — which companies pay providers there.
